US4837027A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Transdermal drug delivery device
Assignee: Alza Corp
•
Filing: 1988-08-09
•
Granted: 1989-06-06
•
Expires: 2008-08-09
Abstract
Abstract A diffusional drug delivery device is described which can provide for stability of the adhesive and system components, elimination of the initial burst of drug and hence irritation, and to provide for delayed onset of therapeutic effect along with delivery of a therapeutic agent at an optimum rate. The therapeutic agent in a first form which is suitable for storage, and the anhydrous activating means are inert when in an anhydrous environment. Moisture activates the system whereby the activating means provides an acidic or basic solution and the first form of the therapeutic agent is converted to a second form which is suitable for absorption through the skin or mucosa.
Inventors
- 👤 Eun S. Lee
- 👤 Su I. Yum
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 10:11
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K9/7084
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
153 words
A controlled release medical device for delivery of at least one therapeutic agent in a pre-determined delivery rate pattern to a biological environment comprising, in combination: reservoir means containing a therapeutic agent which in a first form is suitable for storage and in a second form in suitable for absorption through the skin or mucosa, and said reservoir means having a surface substantially impermeable to said therapeutic agent in said first form and permeable to said therapeutic agent in said second form and through which the second form of said therapeutic agent is released to the biological environment; and activating means containing a plurality of microcapsules containing an activating solution; whereby the therapeutic agent is changed from its first to its second form by release of the activating solution from said microcapsules, and whereby the passage of therapeutic agent to the biological environment by diffusion is impeded until the therapeutic agent changes form.
Claim 2
Dependent Claim
153 words
A controlled release medical device for delivery of at least one therapeutic agent in a pre-determined delivery rate pattern to a biological environment comprising, in combination: reservoir means containing a therapeutic agent which in a first form is suitable for storage and in a second form in suitable for absorption through the skin or mucosa, and said reservoir means having a surface substantially impermeable to said therapeutic agent in said first form and permeable to said therapeutic agent in said second form and through which the second form of said therapeutic agent is released to the biological environment; and activating means containing a plurality of microcapsules containing an activating solution; whereby the therapeutic agent is changed from its first to its second form by release of the activating solution from said microcapsules, and whereby the passage of therapeutic agent to the biological environment by diffusion is impeded until the therapeutic agent changes form.
Claim 3
Dependent Claim
26 words
The device of claim 1 wherein said reservoir means is a matrix having a therapeutic agent dispersed throughout, said means being substantially free of activating agent.
Claim 4
Dependent Claim
10 words
The device of claim 1 wherein said microcapsules are breakable.
Claim 5
Dependent Claim
10 words
The device of claim 1 wherein said microcapsules are meltable.
Claim 6
Dependent Claim
29 words
The device of claim 1 which further comprises: rate controlling means for controlling the rate at which activating agent, once released from the microcapsules, diffuses into said reservoir means.
Claim 7
Dependent Claim
40 words
The device of claim 1 wherein said therapeutic agent is selected from the group consisting of fluorouracil, barbitol, furosemide, albuterol, apomorphine, benzocaine, acetylsalicylic acid, scopolamine, clonidine, phenylpropanolamine, chlorpheniramine, pilocarpine, terbutaline, salbutamol, ephedrine, ergonovine, ergotamine, benzotropine, nicotine, secoverine, propranolol and timolol.
Claim 8
Dependent Claim
128 words
A controlled release medical device for delivery of nicotine in a pre-determined delivery rate pattern to a biological environment comprising, in combination: reservoir means containing nicotine tartrate which is a form of nicotine suitable for storage, said nicotine tartrate being subsequently changed to nicotine which is suitable for absorption through the skin or mucosa, and said reservoir means having a surface substantially impermeable to nicotine tartrate and permeable to nicotine and through which nicotine is released to the biological environment; and activating means containing a plurality of microcapsules containing an activating solution; whereby nicotine tartrate is changed to nicotine by release of the activating solution from said microcapsules, and whereby the passage of nicotine to the biological environment by diffusion is impeded until the nicotine tartrate changed form.
Claim 9
Dependent Claim
128 words
A controlled release medical device for delivery of nicotine in a pre-determined delivery rate pattern to a biological environment comprising, in combination: reservoir means containing nicotine tartrate which is a form of nicotine suitable for storage, said nicotine tartrate being subsequently changed to nicotine which is suitable for absorption through the skin or mucosa, and said reservoir means having a surface substantially impermeable to nicotine tartrate and permeable to nicotine and through which nicotine is released to the biological environment; and activating means containing a plurality of microcapsules containing an activating solution; whereby nicotine tartrate is changed to nicotine by release of the activating solution from said microcapsules, and whereby the passage of nicotine to the biological environment by diffusion is impeded until the nicotine tartrate changed form.
References Cited (Backward Citations)
US3598122B1
Cited
US3598122A
Cited
US3598123A
Cited
US3870593A
Cited
US4177256A
Cited
US3923939A
Cited
US4012221A
Cited
US4144317A
Cited
US4166111A
Cited
US4286592A
Cited
US4314557A
Cited
US4379454A
Cited
US4661105A
Cited
US4568343A
Cited
DE3438284A1
Cited
US4597961A
Cited
EP0197504A2
Cited
US4655766A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-06-05 | 1992-12-05 | 1993-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-06-05 | 1996-12-05 | 1997-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-06-05 | 2000-12-05 | 2001-06-06 | $7700.00 | Window Closed / Lapsed |